226 related articles for article (PubMed ID: 31102256)
1. Detection of cell-free circulating BRAF
Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
[TBL] [Abstract][Full Text] [Related]
2. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
[TBL] [Abstract][Full Text] [Related]
3. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
[TBL] [Abstract][Full Text] [Related]
4. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
[TBL] [Abstract][Full Text] [Related]
5. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
Anforth RM; Carlos GR; Scolyer RA; Chou S; Fernandez-Peñas P
Melanoma Res; 2015 Feb; 25(1):91-4. PubMed ID: 25380183
[TBL] [Abstract][Full Text] [Related]
6. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
[TBL] [Abstract][Full Text] [Related]
7. Massively parallel sequencing analysis of benign melanocytic naevi.
Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
[TBL] [Abstract][Full Text] [Related]
8.
Wang CJ; Cui L; Ma HH; Wang D; Zhang L; Lian HY; Li WJ; Zhang Q; Wang TY; Li ZG; Zhang R
Mol Cancer Ther; 2021 Jul; 20(7):1316-1323. PubMed ID: 33879554
[TBL] [Abstract][Full Text] [Related]
9. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
[TBL] [Abstract][Full Text] [Related]
10. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.
Yeh I; von Deimling A; Bastian BC
J Natl Cancer Inst; 2013 Jun; 105(12):917-9. PubMed ID: 23690527
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
[TBL] [Abstract][Full Text] [Related]
12. Mutational status of naevus-associated melanomas.
Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
14. Activating BRAF mutations in eruptive melanocytic naevi.
Sekulic A; Colgan MB; Davis MD; DiCaudo DJ; Pittelkow MR
Br J Dermatol; 2010 Nov; 163(5):1095-8. PubMed ID: 20716222
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.
Nguyen LP; Emley A; Wajapeyee N; Green MR; Mahalingam M
Br J Dermatol; 2010 Mar; 162(3):677-80. PubMed ID: 19919630
[TBL] [Abstract][Full Text] [Related]
17. Does the gene matter? Genotype-phenotype and genotype-outcome associations in congenital melanocytic naevi.
Polubothu S; McGuire N; Al-Olabi L; Baird W; Bulstrode N; Chalker J; Josifova D; Lomas D; O'Hara J; Ong J; Rampling D; Stadnik P; Thomas A; Wedgeworth E; Sebire NJ; Kinsler VA
Br J Dermatol; 2020 Feb; 182(2):434-443. PubMed ID: 31111470
[TBL] [Abstract][Full Text] [Related]
18. High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.
Duffy DL; Lee KJ; Jagirdar K; Pflugfelder A; Stark MS; McMeniman EK; Soyer HP; Sturm RA
Br J Dermatol; 2019 Nov; 181(5):1009-1016. PubMed ID: 30820946
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions.
Larsen AC; Dahl C; Dahmcke CM; Lade-Keller J; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
Acta Ophthalmol; 2016 Aug; 94(5):463-70. PubMed ID: 27009410
[TBL] [Abstract][Full Text] [Related]
20. Defining the Molecular Genetics of Dermoscopic Naevus Patterns.
Tan JM; Tom LN; Soyer HP; Stark MS
Dermatology; 2019; 235(1):19-34. PubMed ID: 30332666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]